The global cancer registry software market size is expected to reach USD 172.4 million by 2030, registering a CAGR of 12.7% from 2024 to 2030. Growing incidence of cancer is expected to aid growth over the forecast period. Currently, cancer is the second leading cause of death globally, and according to WHO, around 70% of the deaths occur in low- and middle-income countries.
Moreover, rising adoption of Electronic Health Records (EHRs) in developed countries and increasing need for cancer registries for post-marketing surveillance are among the factors further anticipated to boost the demand for cancer registry software in the coming years. Market players are constantly involved in software updation in an attempt to minimize security risks and provide efficient software, thereby increasing market visibility and adoption. For instance, in April 2018, Elekta invested in PalabraApps LLC to improve its MOSAIQ Oncology Information System software.
Increasing number of clinical trials being conducted by major pharmaceutical and biotechnological companies is expected to drive the market over the forecast period. Cancer registry data helps in tracking patients for clinical trials. Moreover, the affected locations for any specific type of cancer can be identified by using this software. Major pharmaceutical companies are increasingly preferring cancer registry software owing to less requirement of internal staff, increased cost-effectiveness, and efficient management of resources, which is further widening the scope for growth.
This product will be delivered within 2 business days.
Moreover, rising adoption of Electronic Health Records (EHRs) in developed countries and increasing need for cancer registries for post-marketing surveillance are among the factors further anticipated to boost the demand for cancer registry software in the coming years. Market players are constantly involved in software updation in an attempt to minimize security risks and provide efficient software, thereby increasing market visibility and adoption. For instance, in April 2018, Elekta invested in PalabraApps LLC to improve its MOSAIQ Oncology Information System software.
Increasing number of clinical trials being conducted by major pharmaceutical and biotechnological companies is expected to drive the market over the forecast period. Cancer registry data helps in tracking patients for clinical trials. Moreover, the affected locations for any specific type of cancer can be identified by using this software. Major pharmaceutical companies are increasingly preferring cancer registry software owing to less requirement of internal staff, increased cost-effectiveness, and efficient management of resources, which is further widening the scope for growth.
Cancer Registry Software Market Report Highlights
- Standalone software dominated the market and accounted for a share of 80.8% in 2023 attributed to its advanced features and easy-to-use tools.
- On the basis of deployment model, on-premise model segment dominated the market and accounted for a share of 59.8% in 2023.
- On the basis of components, the commercial segment dominated the market and accounted for a share of 75.0% in 2023 owing to its advantage of data safety as compared to the public database.
- The government & third-party segment dominated the market and accounted for a share of 27.2% in 2023.
- North America cancer registry software market accounted for the largest revenue share of 44.0% in 2023, owing to the presence of developed infrastructure.
- The Asia Pacific is expected to grow at the fastest CAGR of 14.8% over the forecast period, owing to increasing government initiatives in this region.
The leading players in the Cancer Registry Software market include:
- Elekta
- Oracle
- ONCO, Inc.
- IBM
- MCKESSON CORPORATION
- Conduent, Inc.
- Ordinate Corporation
- Volpara Health Limited
- Health Catalyst
- Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cancer Registry Software Market Variables, Trends, & Scope
Chapter 4. Cancer Registry Software Market: Software Estimates & Trend Analysis
Chapter 5. Cancer Registry Software Market: Deployment Model Estimates & Trend Analysis
Chapter 6. Cancer Registry Software Market: Component Estimates & Trend Analysis
Chapter 7. Cancer Registry Software Market: End-use Estimates & Trend Analysis
Chapter 8. Cancer Registry Software Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
Companies Mentioned
The leading players in the Cancer Registry Software market include:- Elekta
- Oracle
- ONCO, Inc.
- IBM
- MCKESSON CORPORATION
- Conduent, Inc.
- Ordinate Corporation
- Volpara Health Limited
- Health Catalyst
- Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 75.8 Million |
| Forecasted Market Value ( USD | $ 172.4 Million |
| Compound Annual Growth Rate | 12.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
